鱼跃医疗
(002223)
| 流通市值：336.95亿 | | | 总市值：359.29亿 |
| 流通股本：9.40亿 | | | 总股本：10.02亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 6,544,895,742.68 | 4,658,967,431.03 | 2,435,873,177.34 | 7,565,819,017.28 |
| 营业收入 | 6,544,895,742.68 | 4,658,967,431.03 | 2,435,873,177.34 | 7,565,819,017.28 |
| 二、营业总成本 | 5,187,824,391.82 | 3,579,183,683.09 | 1,816,105,564.51 | 5,947,065,140.88 |
| 营业成本 | 3,249,593,235.42 | 2,312,457,767.92 | 1,210,554,322.86 | 3,772,269,938.71 |
| 税金及附加 | 62,066,173.32 | 44,346,091.89 | 22,709,209.4 | 74,424,745.76 |
| 销售费用 | 1,232,547,528.65 | 812,432,951.98 | 362,944,479.94 | 1,361,398,321.47 |
| 管理费用 | 339,196,375 | 219,566,853.95 | 102,042,045.73 | 428,230,197.9 |
| 研发费用 | 444,570,559.97 | 295,071,504.55 | 156,329,663.86 | 546,683,621.93 |
| 财务费用 | -140,149,480.54 | -104,691,487.2 | -38,474,157.28 | -235,941,684.89 |
| 其中:利息费用 | - | - | 562,486.15 | 20,727,024.98 |
| 其中:利息收入 | 172,420,498.89 | 120,572,298.5 | 47,533,147.99 | 237,918,841.43 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 34,974,001.74 | 32,692,343.07 | 764,972.84 | 23,206,208.79 |
| 资产处置收益 | 1,067,120.71 | 1,249,796.19 | -75,696.74 | 6,161,857.24 |
| 资产减值损失(新) | -9,624,422.43 | -9,524,443.91 | -92,792.72 | -46,990,377.29 |
| 信用减值损失(新) | -24,045,999.88 | -26,682,106.57 | -23,124,867.68 | -21,075,478.18 |
| 其他收益 | 325,588,275.08 | 309,347,676.27 | 139,661,777.6 | 351,524,971.91 |
| 四、营业利润 | 1,685,030,326.08 | 1,386,867,012.99 | 736,901,006.13 | 1,931,581,058.87 |
| 加:营业外收入 | 1,863,016.25 | 1,463,787.54 | 815,437.43 | 5,047,708.19 |
| 减:营业外支出 | 2,560,464.88 | 1,230,372.8 | 617,028.34 | 3,800,215.94 |
| 五、利润总额 | 1,684,332,877.45 | 1,387,100,427.73 | 737,099,415.22 | 1,932,828,551.12 |
| 减:所得税费用 | 218,034,227.66 | 187,433,372.28 | 113,916,798.46 | 128,562,201.92 |
| 六、净利润 | 1,466,298,649.79 | 1,199,667,055.45 | 623,182,616.76 | 1,804,266,349.2 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 1,466,298,649.79 | 1,199,667,055.45 | 623,182,616.76 | 1,804,266,349.2 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 1,466,043,552.13 | 1,202,704,408.78 | 624,758,641.94 | 1,805,700,655.26 |
| 少数股东损益 | 255,097.66 | -3,037,353.33 | -1,576,025.18 | -1,434,306.06 |
| 扣除非经常损益后的净利润 | 1,169,266,533.55 | 913,718,165.11 | 512,650,334.35 | 1,392,839,113.19 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.47 | 1.2 | 0.63 | 1.81 |
| (二)稀释每股收益 | 1.47 | 1.2 | 0.63 | 1.81 |
| 八、其他综合收益 | -25,254,882.74 | -42,485,052.57 | -53,795,499.78 | 157,085,418.17 |
| 归属于母公司股东的其他综合收益 | -28,877,933.06 | -46,393,514.36 | -54,873,702.36 | 158,478,569.91 |
| 九、综合收益总额 | 1,441,043,767.05 | 1,157,182,002.88 | 569,387,116.98 | 1,961,351,767.37 |
| 归属于母公司股东的综合收益总额 | 1,437,165,619.07 | 1,156,310,894.42 | 569,884,939.58 | 1,964,179,225.17 |
| 归属于少数股东的综合收益总额 | 3,878,147.98 | 871,108.46 | -497,822.6 | -2,827,457.8 |
| 公告日期 | 2025-10-25 | 2025-08-23 | 2025-04-26 | 2025-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |